These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 30426720)

  • 21. Noninvasive Prediction of IDH1 Mutation and ATRX Expression Loss in Low-Grade Gliomas Using Multiparametric MR Radiomic Features.
    Ren Y; Zhang X; Rui W; Pang H; Qiu T; Wang J; Xie Q; Jin T; Zhang H; Chen H; Zhang Y; Lu H; Yao Z; Zhang J; Feng X
    J Magn Reson Imaging; 2019 Mar; 49(3):808-817. PubMed ID: 30194745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiomics features to distinguish glioblastoma from primary central nervous system lymphoma on multi-parametric MRI.
    Kim Y; Cho HH; Kim ST; Park H; Nam D; Kong DS
    Neuroradiology; 2018 Dec; 60(12):1297-1305. PubMed ID: 30232517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fusion Radiomics Features from Conventional MRI Predict MGMT Promoter Methylation Status in Lower Grade Gliomas.
    Jiang C; Kong Z; Liu S; Feng S; Zhang Y; Zhu R; Chen W; Wang Y; Lyu Y; You H; Zhao D; Wang R; Wang Y; Ma W; Feng F
    Eur J Radiol; 2019 Dec; 121():108714. PubMed ID: 31704598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo characterization of physiological and metabolic changes related to isocitrate dehydrogenase 1 mutation expcression by multiparametric MRI and MRS in a rat model with orthotopically grafted human-derived glioblastoma cell lines.
    Clément A; Doyen M; Fauvelle F; Hossu G; Chen B; Barberi-Heyob M; Hirtz A; Stupar V; Lamiral Z; Pouget C; Gauchotte G; Karcher G; Beaumont M; Verger A; Lemasson B
    NMR Biomed; 2021 Jun; 34(6):e4490. PubMed ID: 33599048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diffusion tensor imaging radiomics in lower-grade glioma: improving subtyping of isocitrate dehydrogenase mutation status.
    Park CJ; Choi YS; Park YW; Ahn SS; Kang SG; Chang JH; Kim SH; Lee SK
    Neuroradiology; 2020 Mar; 62(3):319-326. PubMed ID: 31820065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiomics may increase the prognostic value for survival in glioblastoma patients when combined with conventional clinical and genetic prognostic models.
    Choi Y; Nam Y; Jang J; Shin NY; Lee YS; Ahn KJ; Kim BS; Park JS; Jeon SS; Hong YG
    Eur Radiol; 2021 Apr; 31(4):2084-2093. PubMed ID: 33006658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiomics in peritumoral non-enhancing regions: fractional anisotropy and cerebral blood volume improve prediction of local progression and overall survival in patients with glioblastoma.
    Kim JY; Yoon MJ; Park JE; Choi EJ; Lee J; Kim HS
    Neuroradiology; 2019 Nov; 61(11):1261-1272. PubMed ID: 31289886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.
    Wang K; Wang Y; Fan X; Wang J; Li G; Ma J; Ma J; Jiang T; Dai J
    Neuro Oncol; 2016 Apr; 18(4):589-97. PubMed ID: 26409566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary central nervous system lymphoma and atypical glioblastoma: Differentiation using radiomics approach.
    Suh HB; Choi YS; Bae S; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
    Eur Radiol; 2018 Sep; 28(9):3832-3839. PubMed ID: 29626238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiomics-based prediction of multiple gene alteration incorporating mutual genetic information in glioblastoma and grade 4 astrocytoma, IDH-mutant.
    Sohn B; An C; Kim D; Ahn SS; Han K; Kim SH; Kang SG; Chang JH; Lee SK
    J Neurooncol; 2021 Dec; 155(3):267-276. PubMed ID: 34648115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma.
    Lasocki A; Tsui A; Gaillard F; Tacey M; Drummond K; Stuckey S
    J Clin Neurosci; 2017 May; 39():170-175. PubMed ID: 28214089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma.
    Yamashita K; Hatae R; Hiwatashi A; Togao O; Kikuchi K; Momosaka D; Yamashita Y; Kuga D; Hata N; Yoshimoto K; Suzuki SO; Iwaki T; Iihara K; Honda H
    Diagn Interv Imaging; 2019; 100(7-8):411-419. PubMed ID: 30948344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diffusion radiomics as a diagnostic model for atypical manifestation of primary central nervous system lymphoma: development and multicenter external validation.
    Kang D; Park JE; Kim YH; Kim JH; Oh JY; Kim J; Kim Y; Kim ST; Kim HS
    Neuro Oncol; 2018 Aug; 20(9):1251-1261. PubMed ID: 29438500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MR Imaging-Based Analysis of Glioblastoma Multiforme: Estimation of IDH1 Mutation Status.
    Yamashita K; Hiwatashi A; Togao O; Kikuchi K; Hatae R; Yoshimoto K; Mizoguchi M; Suzuki SO; Yoshiura T; Honda H
    AJNR Am J Neuroradiol; 2016 Jan; 37(1):58-65. PubMed ID: 26405082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiregional-Based Magnetic Resonance Imaging Radiomics Combined With Clinical Data Improves Efficacy in Predicting Lymph Node Metastasis of Rectal Cancer.
    Liu X; Yang Q; Zhang C; Sun J; He K; Xie Y; Zhang Y; Fu Y; Zhang H
    Front Oncol; 2020; 10():585767. PubMed ID: 33680919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel 3D magnetic resonance fingerprinting radiomics in adult brain tumors: a feasibility study.
    Tippareddy C; Onyewadume L; Sloan AE; Wang GM; Patil NT; Hu S; Barnholtz-Sloan JS; Boyacıoğlu R; Gulani V; Sunshine J; Griswold M; Ma D; Badve C
    Eur Radiol; 2023 Feb; 33(2):836-844. PubMed ID: 35999374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of Prognosis in Glioblastoma Using Radiomics Features of Dynamic Contrast-Enhanced MRI.
    Pak E; Choi KS; Choi SH; Park CK; Kim TM; Park SH; Lee JH; Lee ST; Hwang I; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
    Korean J Radiol; 2021 Sep; 22(9):1514-1524. PubMed ID: 34269536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiomics risk score may be a potential imaging biomarker for predicting survival in isocitrate dehydrogenase wild-type lower-grade gliomas.
    Park CJ; Han K; Kim H; Ahn SS; Choi YS; Park YW; Chang JH; Kim SH; Jain R; Lee SK
    Eur Radiol; 2020 Dec; 30(12):6464-6474. PubMed ID: 32740813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
    Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H
    J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deep Learning Radiomics for the Assessment of Telomerase Reverse Transcriptase Promoter Mutation Status in Patients With Glioblastoma Using Multiparametric MRI.
    Zhang H; Zhang H; Zhang Y; Zhou B; Wu L; Lei Y; Huang B
    J Magn Reson Imaging; 2023 Nov; 58(5):1441-1451. PubMed ID: 36896953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.